SEOUL, Aug. 21 (Yonhap) -- South Korean digital health care startup HoneyNaps Co. said Monday its artificial intelligence-based sleep diagnostic software, Somnum, has won approval for sale from U.S. drug authorities.
The U.S. Food and Drug Administration (FDA) granted Section 510(k) clearance, or premarket notification, to Somnum, demonstrating that the medical device is safe and effective. The cleared device does not need to win premarket approval before hitting the shelves.
This image provided by HoneyNaps Co. shows its sleep diagnostic software, Somnum. (PHOTO NOT FOR SALE) (Yonhap)
It is the first FDA approval won by a sleep analysis solution developed by a South Korean company. Two U.S. companies -- EnsoData's EnsoSleep and Cerebra Medical's Cerebra Sleep System -- have received FDA clearance.
"The FDA has strengthened its review process of AI-based health care products," HoneyNaps said in a release. "We have carried out clinical trials in the U.S. for the past three years to meet the FDA criteria."
Somnum is software with an AI algorithm that collects and analyzes sleep data, mainly the vital signs of its user, and predicts disease by applying it to a clinical data set. Its AI has been trained with more than 18 million sets of related data over the past eight years.
HoneyNaps said the FDA approval will help the company go public in South Korea and put more effort into expanding its business horizons to include cerebral and cardiovascular diseases.
This image provided by HoneyNaps Co. shows the front page of the U.S. Food and Drug Administration's approval for its sleep diagnostic software, Somnum. (PHOTO NOT FOR SALE) (Yonhap)
brk@yna.co.kr
(END)
